Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
For Gossamer Bio, the average analyst Fair Value has shifted from about US$3.86 to about US$1.66 per share, which marks a meaningful reset in price targets. Research commentary links this move to a split view on risk, funding and execution, with more cautious analysts focusing on dilution and going concern warnings, while bullish voices still point to the seralutinib regulatory path and balance sheet work. As you read on, you will see how these changing assumptions shape the evolving Gossamer Bio story and how to track it over time.
Stay updated as the Fair Value for Gossamer Bio shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Gossamer Bio.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Leerink shifted Gossamer Bio to an Outperform rating with a US$1 price target and points to the FDA focus on totality of data for seralutinib, including PROSERA, TORREY and subgroup analyses.
-
Piper Sandler keeps an Overweight rating even after cutting its target to US$4 from US$15 and highlights that the FDA treated PROSERA statistics as a review topic rather than a barrier to filing the seralutinib NDA.
-
H.C. Wainwright maintains a Buy rating with a US$2 target and views the convertible note exchange as removing a balance sheet overhang through potential seralutinib approval.
🐻 Bearish Takeaways
-
Barclays keeps an Underweight rating and trims its target to US$0.28 from US$0.30, stressing that the 2027 note exchange, while reducing debt and extending maturity, is meaningfully equity dilutive.
-
Goldman Sachs suspends its rating, target and estimates, citing the going concern warning and uncertainty around Gossamer Bio's ability to secure additional capital to fund operations.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 5 risks for Gossamer Bio. See which could impact your investment.
How This Changes the Fair Value For Gossamer Bio
-
Fair value for Gossamer Bio has moved from about US$3.86 to about US$1.66 per share.
-
Revenue growth assumptions have shifted from about 42.09% to about 35.91%.
-
Net profit margin in analyst models has changed from roughly 7.45% to about 17.91%.
-
The future P/E applied to Gossamer Bio has moved from about 116.42x to about 52.50x.
-
The discount rate used in analyst models has moved from roughly 11.58% to about 8.30%.
Never Miss an Update: Follow The Narrative
Narratives link Gossamer Bio's clinical and financing story to a forward-looking forecast and fair value, updating as new data and news arrive. They help you see how changing assumptions about trials, partnerships and cash impact the overall thesis.
Head over to the Simply Wall St Community and follow the Narrative on Gossamer Bio to stay up to date on:
-
How the PROSERA Phase III study in pulmonary arterial hypertension and the CIRANATA Phase III study in PH ILD shape expectations for seralutinib.
-
The potential impact of Gossamer Bio's global footprint, including interest from large PAH markets, and the anticipated positioning of seralutinib as a potential first in class treatment.
-
Key risks such as heavy R&D spending relative to revenue, reliance on seralutinib trial outcomes and Gossamer Bio's limited cash runway into the first half of 2027.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GOSS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
